DURECT Corporation
0.82
-0.01 (-0.61%)
At close: Jan 14, 2025, 3:59 PM
0.85
3.63%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 0.6
Market Cap 25.46M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.64
PE Ratio (ttm) -1.28
Forward PE n/a
Analyst Hold
Ask 0.88
Volume 169,827
Avg. Volume (20D) 107,091
Open 0.82
Previous Close 0.82
Day's Range 0.79 - 0.85
52-Week Range 0.62 - 1.88
Beta undefined

About DRRX

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in...

Sector Healthcare
IPO Date Sep 28, 2000
Employees 48
Stock Exchange NASDAQ
Ticker Symbol DRRX

Analyst Forecast

According to 2 analyst ratings, the average rating for DRRX stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 509.61% from the latest price.

Buy 50.00%
Hold 50.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

DURECT Corporation is scheduled to release its earnings on Mar 26, 2025, during market hours.
Analysts project revenue of $6.91M, reflecting a 158.90% YoY growth and earnings per share of -0.02, making a -80.00% decrease YoY.
8 months ago · Source
-14.02%
DURECT shares are trading lower after the company ... Unlock content with Pro Subscription